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Background: Current guidelines in Primary Biliary Cholangitis ( PBC) recommend routine 
screening for symptoms in PBC. However, at present there are no validated practical tools 
suitable for screening use in practice. 
Aim: The purpose of this study was to develop a short quality of life questionnaire for in PBC. 
Methods: The short PBC HRQL questionnaire was derived and validated by analysing the 
PBC-40 questionnaires from the UK-PBC Research Cohort. Construct validity was assessed 
using European Quality of Life Five Dimensions (EQ5D) questionnaire. Test-retest analysis 
was done by asking a subgroup of patients to complete the questionnaire twice within 2-4 
weeks.  
Results: A total of 2219 patients completed PBC-40 questionnaire in 2013. Stepwise 
regression identified 10 questions that contributed to more than 95% of the PBC-40 score 
variance and covered the main domains of PBC. The short HRQL questionnaire, PBC-10, 
had good internal consistency (Cronbach's α 0.905) and item-total correlations. PBC-10 
demonstrated no ceiling effects but a floor effect was noted. Further validation on 2502 
patients who completed the PBC questionnaire in 2017 confirmed the psychometric 
properties of PBC-10. Further analysis on 186 patients showed that PBC-10 demonstrated 
good internal consistency (Cronbach's α = 0.936), had good reproducibility (intraclass 
correlation coefficient = 0.945), good correlation with the EQ5D (r = 0.736), and was 
responsive to change. A change of 4 points in the PBC-10 score would be considered 
clinically important. 
Conclusion: PBC-10 is a short and valid questionnaire for assessing the HRQL in patients 
with PBC in clinical practice. 
 
 
Key words: Health related quality of life; Primary Biliary Cholangitis; Patient reported 









Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease. An often asymptomatic 
early phase is typically followed by the progressive development of disease-related symptoms 
which can have a significant impact on life quality [1, 2]. Typical PBC-related symptoms 
include fatigue, pruritus, dry eyes and mouth, and occasional abdominal and bone pain [3, 4]. 
Fatigue can be profound and persistent, and is typically unrelated to histological stage or 
activity of the disease [5-7].  
Recent years have seen significant evolution in the treatment of PBC. Furthermore, the 
importance of health-related quality of life (HRQoL) [8] is widely appreciated, and approaches 
to the management of the symptoms contributing to HRQoL, most notably pruritus, continues 
to improve. HRQoL provides insights into how patients perceive their own disease processes, 
which understandably may be different from the way they are perceived by clinicians. 
Considering the importance of symptoms and their impact on the quality of life of patients all 
current guidelines, including those from the British Society of Gastroenterology [1] and the 
European Association for the Study of the Liver [9], recommend routine screening for the 
presence of symptoms in PBC. None of these guidelines, however, suggest how such 
screening should be achieved in practice, and at present there are no validated tools suitable 
for screening use in practice.  
In contrast to the low level of routine assessment in clinical practice, research assessment of 
symptoms and HRQoL in PBC has been extensive. Much of this research has been 
undertaken using the PBC-40 [3], a patient derived disease specific HRQoL measure validated 
for self-completion by PBC patients. Although PBC-40 is a valuable research tool (including 
as a patient reported outcome measure in trials of new therapies) it is too lengthy and time 
consuming to use in normal clinical practice. Given the importance of symptoms and HRQoL 
in PBC, the emergence of new treatments which can target these symptoms[10-12], and the 
guideline recommendation that clinicians screen for PBC symptoms on an annual basis there 
is a pressing need for a valid, short and practical symptom screening tool that is suitable for 
routine  use in patients with PBC at the point of care. 
The purpose of this study was to use rigorous statistical methods to develop and validate a 
short version of the PBC-40 quality of life questionnaire for clinical use. The short version 
would address the clinical need for a rigorously developed, valid, simple and short measure, 









Phase 1: Shortening the PBC-40: 
This phase was completed by analysing the PBC-40 questionnaire data from the UK PBC 
registry obtained in 2013. PBC-40 questionnaire reduction was done using stepwise 
regression analysis of the total scores on the individual items [13,14, 15]. We selected the 
items that represented most of the variation in the PBC-40 scores that covered the main 
domains in PBC related quality of life [3].  To explore the underlying domains/themes, we used 
Principal Components analysis (PCA) on the PBC-40 questions, using the approach of 
varimax rotation to simplify the analysis of the principal factors [16,17]. 
Internal consistency (as assessed using Cronbach α) of the short questionnaire was 
determined acceptable if it was between 0.7 and 0.9. In addition to the main PBC-40 
questions, patients were asked to rate their general health on a 5-point scale from poor to 
excellent to assess the construct validity of the short PBC QoL measure. 
We assessed the correlation of each item with the total score as a measure of internal 
reliability. It has been proposed that the accepted range is between 0.2 to 0.8 [20]. Maximum 
response rate should be between 20-80%. Items with lower or higher values were considered 
as candidates for exclusion because they added little value to the health outcome measure 
[20, 21]. 
We examined the distribution of the patients’ scores for flooring and ceiling effect looking at 
the central tendency of the values, using mean, median as well as standard deviation and 
range. If there were no ceiling or floor effects, the data distribution should be in a normal or 
bell shape pattern. Skewness of the data was also examined. We took a skewness value of -
1 to +1 as acceptable [22].  If more than 15% of patients score the lowest or highest possible 
score, respectively, we would consider that the short version of PBC QoL would have floor or 
ceiling effects respectively [22]. 
We assessed the face and content validity of the proposed short version of PBC QoL. We 
consulted eight experts in the field to judge face and content validity. We used the content 
validity index proposed by Lynn in 1986 [23]. It includes a two-step method for determining 
content validity by calculating a content validity index (CVI). When there are six or more 
panellists, the CVI is advisable to be higher than 0.78. We also computed the CVI of the items 
and the CVI of the overall scale [24]. The CVI of the overall measure is the proportion of items 
on an instrument that achieved a rating of 3 or 4. A CVI of 0.70 represents average agreement; 






Phase 2: Validation of the short version of PBC QoL: 
In order to confirm the validity of the short version of PBC-QoL, we analysed the psychometric 
properties of the short version of PBC questionnaire using the data collected from the PBC 
database of patients who returned the PBC-40 questionnaire in 2017. We confirmed the 
psychometric properties of the short version of the PBC-QoL; item-total correlation, items 
response rate, ceiling and flooring effect, and Cronbach α reliability.  
 
Phase 3: Further evaluation of the short version of PBC QoL 
To check the psychometric characteristics of the short version of PBC questionnaire, a 
convenience group of patients with PBC were asked to complete the PBC-10 questionnaire 
on two occasions, 2-4 weeks apart by post. Participants were first identified from the previously 
completed PBC-40 questionnaires.  The participants were selected randomly. In addition to 
the quality of life questions, patients were asked to report information of treatments.   
The retest questionnaire , which was sent 2-4 weeks after the first set,  included a 5-point 
transition question asking participants whether their general health had improved slightly, 
much improved, got worse slightly, got much worse, or remained the same since completing 
the first questionnaire. The principal aim of the validation phase of the study was to evaluate 
the final psychometric properties of the measure against established criteria. We examined 
the following psychometric properties of the short PBC QoL [20, 25]: 
1. We assessed construct validity by calculating Pearson’s correlation coefficient (r) 
against the EQ5D generic QoL. An appropriate correlation coefficient for construct 
validity should be somewhere between 0.4 and 0.8. 
2. We assessed the test-retest reliability including those patients who reported no change 
in their condition. An intra-class correlation (ICC) between the first and second 
completion of the PBC should exceed 0.75 for good reproducibility. 
3. We assessed the responsiveness statistics of the short PBC QoL in those patients who 
reported a change in their health status (got worse or improved) at the time of the 1- 
month follow up questionnaire. We calculated three responsiveness statistics, which 
were: effect size, standardised response mean (SRM) and the responsiveness ratio.  
The acceptable value for responsiveness ratio is 0.5 or 50%. The effect size and SRM 
cut-offs were defined as: 0.2–<0.5, small; 0.5–<0.8, medium; ≥0.8, large [20,26]. 
4. We calculated the minimal important change (MIC), which is the minimum change in 





short PBC QoL [27]. It is recommended that the patient's perspective is used to 
measure the MIC [28]. MIC is defined as the mean change of the scores of patients 
who had improved or got worse “slightly” on the retest questionnaire. 
 
Results: 
Phase 1: Shortening the PBC-40: 
We analysed the dataset of 2219 patients who completed PBC-40 in 2013 to derive the short 
PBC-QoL (Table 1). Regressing the total PBC-40 questions on the total score identified 10 
questions (Appendix 1) that contributed more than 95% of the variance and covered the main 
domains of PBC-40. These questions were therefore chosen for the short form of PBC-QoL 
measure (henceforth referred to as PBC-10) (Table 2).  
Items in the PBC-10 had good internal consistency (Cronbach's α 0.905) and item-total 
correlations between 0.2-0.8. PBC-10 demonstrated a good correlation with the general health 
question (Pearson correlation co-efficient 0.558) and, unsurprisingly, with PBC-40 (r=0.978).  
Using the 15% recommended value for the percentage of patients who score the highest or 
the lowest [22], the PBC-10 demonstrated no ceiling effects, apart from questions 8 which had 
a small ceiling effect of 16.6% (Table 3). Skewness values of all 10 items were acceptable 
and ranged between 0-1.  However, a floor effect was noted in all 10 questions (Table 3). The 
content validity index (CVI) of the PBC-10 of the whole index was 1.00, which is good. 
Individual CVI ranged between 0.5 -1.0. 
Principal component analysis (PCA):  
The Kaiser-Meyer-Olkin measure of sampling adequacy (KMO=0.0.908) and Bartlett’s test of 
sphericity (p<0.001) confirmed that the sample was good enough for PCA.  Attribution of the 
10 items of PBC-10 to their factors showed that the items covered all 6 quality of life domains 
identified in the PBC-40 previously which provided good representation of all different QoL 
aspects of patients with PBC (Table 4).  
Scoring of PBC-10: Responses were scores on a Likert scale from 1-5 . The resulting PBC-
10 score sums up all the 10 questions scores to yield the total score; the range of scores can 








Phase 2: Validation of the short version of PBC QoL: 
We carried out further validation of the PBC-10 on the second cohort of 2502 patients with 
PBC who completed the PBC-40 in 2017 (2251 (90%) females , 251 (10%) males). Mean age 
was 66 years (SD10)). Results showed that PBC-10 had good internal consistency 
(Cronbach's α was 0.915). Psychometric analysis showed good item-total correlations and 
maximum response rate within the recommended range (Table 5). There were no ceiling 
effects but a floor effect was obvious, as discussed above. Skewness value remained within 
the acceptable range of -1 to +1 [22]. 
Phase 3: Further evaluation of the short version of PBC QoL 
A total of 186 patients completed the PBC-10 questionnaires (169 (91%) females,17 (9.1%) 
males). Mean age was 71 years (SD10.86)). Medications use was reported in 169 patients; 
165 patients were taking Ursodeoxycholic acid, one patient was taking Ursodeoxycholic acid 
and obeticholic acid and 2 patients were taking Ursodeoxycholic acid and fibrate and one 
patient reported taking only fibrate.  For the test-retest study, 172 (93%) returned the re-test 
questionnaires within 2-4 weeks. A total of 118 (69%) patients reported no change and their 
data were used to examine the test-retest reliability. A total of 54 (31%) patients reported a 
change and were included in the responsiveness analysis. 
The results showed that PBC-10 correlated well with the EQ5D (r = 0.736 p < 0.005). Internal 
consistency was excellent with Cronbach α of 0.936. Intra-class correlation of the test-retest 
questionnaires was excellent (ICC = 0.945 p < 0.005). Responsiveness statistics showed 
responsiveness ratio of 0.38, effect size of 0.39 and standardised response mean of 1.25.  
With regards to the interpretability of PBC-10, the minimal important change was 3.539 which, 
when rounded up, means that a change of 4 points in the PBC-10 score would be considered 
clinically important.  
 
DISCUSSION 
In this study we developed and validated a brief quality of life measure for patients with PBC, 
the PBC-10, suitable for use as a screening and monitoring tool in routine clinical practice.  
The PBC-10 was derived from the original PBC-40 questionnaire [3] using the extensive UK-
PBC Research Cohort and a stepwise regression analysis technique to select the smallest 
number of items that represent the majority of the PBC-40 scores. The ten items of the PBC-
10 covered all domains of the PBC-40 and explained more than 95% of the variance of the 





shortening any questionnaire is the possibility of compromising its psychometric properties of 
validity and reliability. However, the PBC-10 demonstrated a high degree of validity and 
reliability on subsequent analysis of the dataset collected from 2502 patients with PBC. It had 
a good Cronbach α, well above the threshold of 0.7 recommended in the literature [20].PBC-
10 items correlated very well with the total score with item-total correlations ranging between 
the recommended 0.2-0.8. The content and face validity of PBC-10 was confirmed by 
consultation with hepatology experts in PBC. Principal Component Analysis showed that PBC-
10 items correlated very well with all the six PBC specific quality of life domains (symptoms, 
itch, fatigue, cognition, social, and emotional) which provides good representation of all 
different QoL aspects of patients with PBC. Scoring of PBC-10 is very simple to compute. We 
gave all questions equal weighting, to keep the calculation simple and based on the 
assumption that each domain of QoL is equally important to the individual responding [29]. 
In further evaluation, PBC-10 correlated very well with other generic measures of the quality 
of life (EQ5D and general health questions we used in the study).  PBC-10 had good test-re-
test reliability with an ICC values 0.945. Responsiveness analysis showed that the PBC-10 
had small to moderate responsiveness values. Only 54 (31%) patients reported a change in 
their general health in 2-4 weeks and were included in the responsiveness analysis. The small 
proportion of patients who reported change may have impacted on the evaluation of the 
responsiveness assessment. A change of 4 points or more in the total PBC-10 score would 
be considered as the minimal important change ( MIC) which is 10% of the possible range of 
PBC-10 scores ( 10-50).  MIC score change was noted in 18 (10%) in the re-test 
questionnaires. Due to the small proportion of patients who reported a change, the 
responsiveness and MIC properties of PBC-10 will need further validation in a large cohort of 
patients. 
Although we have not asked the patients about the time needed to complete the PBC-10, we 
believe it will take less time to complete it is significantly shorter than the PBC-40 and consists 
of only 10 questions. More importantly, the interpretation by the clinician takes less time and 
it is therefore much “nimbler” for everyday use. Scoring the PBC-40 can be quite complex 
unless he clinicians are familiar with it (domains are mixed up and some questions are scored 
in reverse. For this, as well as the patient reasons, PBC-40 is not currently used in routine 
clinical practice. Hence the issue. A brief score that is used is always more valuable than a 
detailed score if that detailed score is complex to use.  
When the original  PBC-40 questionnaire was developed [3], there were no ceiling effects but 
there was a noticeable floor effect in the itch domain (36.7%) in PBC-40, which is again 





Another possible reason for the floor effect in PBC quality of life questionnaires is the 
penetrance of pruritus being incomplete. A recent paper showed that about a third of PBC 
patients have no itch at all at any point in their disease [30]. 
There was no evaluation of the responsiveness in the original study that developed PBC-40 
questionnaire [3]. Responsiveness can only be properly assessed when there is a significant 
change in the disease progression. PBC is a chronic illness and the majority of symptoms in 
PBC do not respond quickly to any current treatment [31,32] and therefore responsiveness is 
a challenge to assess (the lack of such treatments was a actually a main driver for 
measurement tools that would help us develop future treatments. Current treatments, except 
liver transplantation [33,34], will not results in a significant quick change in disease outcome 
within a short period to allow quantifying the responsiveness of the PBC-10. However, 
validation is an ongoing process and it is imperative to be able to test and further develop 
PBC-10 in future studies to establish PBC-10 responsiveness and MIC (Minimal important 
change). 
We propose the use of PBC-10 as a quick screening tool for symptoms as well as assess 
response to treatment in patients with PBC. We recommend using PBC-10 in routine clinical 
setting as a quick symptoms screening questionnaire as well as research or clinical trials to 
screen for symptoms, as recommended by the international societies [1, 9].  The measure was 
developed using rigorous statistical and methodological approach using currently 
recommended guidelines [22] in a large patient cohort. In chronic conditions such as PBC, it 
is important to measure treatment in terms of impact on quality of life not just survival [35]. 
Having good face and content validity will encourage patients and clinicians’ engagement to 
use the PBC-10 questionnaire.  Items that are seen irrelevant may cause respondents to not 
take them seriously or decline to answer. 
PBC-10 did not have a significant ceiling effect which means it has good ability to measure 
QoL in patients with severe symptoms. However, flooring effects were observed with PBC-10. 
This could have happened because the majority of patient in the study were managed in the 
outpatient setting with stable and less severe symptoms. Stepwise regression analysis 
showed that the questions beyond question number 8 had minimal contribution to the total 
score but significant floor effect. However, as they are clinically very relevant, they were 
included in PBC-10.  Additional studies are needed to further examine the flooring and ceiling 
effects of PBC-10 in other setting such as following a therapeutic intervention. 
There is no published rule defining the number of patients required to validate a QoL measure. 





that a minimum of 100 patients is sufficient for a proper validation study [22]. Therefore, the 
sample size used for the current study more than fulfils the guidance for developing and 
shortening a QoL measure. Further studies will be needed to confirm the psychometric 
properties of the PBC10 in different samples of patients, including in other cultural groups and 
settings.  
The focus of this study was to develop and psychometrically validate a short tool to measure 
the quality of life in patients with PBC. Therefore, the questionnaires that were completed by 
the UK-PBC cohort group in 2013 and again in 2017 did not include specific questions about 
treatment. As new treatment options are emerging in PBC, more validation studies will be 
needed to assess the QoL of patients using different treatments.  
Fatigue and cognitive symptoms are not specific for PBC but remain an issue that is common 
in the PBC and important to patients.  As a screening tool, PBC-10 can establish the presence 
of those symptoms. Future studies will help to examine the effect of co-morbidities related 
symptoms on the QoL in PBC.  
There is an unavoidable selection bias when asking patients to fill in questionnaires, as not all 
of them will be willing to participate. However, the sample was drawn from a large cohort of 
patients with PBC from different parts of the UK to ensure a good representation of patients 
and to mirror routine clinical practice. 
Our findings support the validity, internal reliability, and reproducibility of the PBC-10, a short 
QoL tool for patients with PBC. PBC-10 had small to moderate responsiveness and noticeable 
floor effect. Therefore, further validation is needed in this aspect. PBC-10 is shorter and can 
be more easily applied in clinical practice than existing QoL measures. We therefore hope that 
it will be widely used, both in normal clinical practice and in health care evaluation to assess 
the effect of interventions on QoL. The simplicity, validity and reliability of the PBC-10 make it 
a strong candidate for PBC clinical registries and databases, and in audits that assess the 












Table 1: Characteristics of the patients who completed the baseline PBC-40 questionnaire  
Table 2: The PBC-10 questionnaire  
Table 3 Flooring and ceiling effect of PBC-10 
Table 4: Correlation of the PBC-10 items with the 6 subdomains of the PBC QoL . 
Table 5: Further validation and psychometric properties of PBC-10 
 
Appendix 1: Stepwise regression and items reduction of the PBC-40 and the psychometric 
properties of the PBC-10 questions. 
 
Table 1: Characteristics of the patients who completed the baseline PBC-40 
questionnaire * 
Total  2219 
Age 65 (10.85) years 
Gender   
     Male 262 (11.81%) 
     Female  1957 ( 88.19%) 
PBC-40 score 96.25 ( 34.03) 
Individual domains score:   
      Symptoms 18.18 (4.57) 
       Itch 5.27 (4.49) 
       Fatigue 29.74 (11.34) 
       Cognition 13.20 (6.29) 
       Social  24.23 (9.82) 
       Emotional  7.69 3.51) 
 
* Categorical data are presented as numbers(percentages). Continuous data are presented 








Table 2: PBC-10 questionnaire 
PBC-10 questions  
 
Please answer all the questions to the best of your ability. If a particular question does not 
apply to you, or you do not know the answer to a particular question, simply write this on the 
questionnaire.  
 
IN THE LAST FOUR WEEKS, how often did you experience any of the following? 
 
1. I have felt embarrassed 
because of the itching 
Never Rarely Occasionally Frequently Always Does 
not 
apply 
2. If I eat or drink a small 
amount and still felt bloated 
Never Rarely Occasionally Frequently Always Does 
not 
apply 
3. My mouth was very dry Never Rarely Occasionally Frequently Always Does 
not 
apply 
4. Fatigue interfered with my 
daily routine 
Never Rarely Occasionally Frequently Always Does 
not 
apply 
5. I had to force myself to do the 
things I needed to do 
Never Rarely Occasionally Frequently Always Does 
not 
apply 
6. If I was busy one day I 
needed at least another day 
to recover 
Never Rarely Occasionally Frequently Always Does 
not 
apply 
7. Because of PBC, I found it 
difficult to concentrate on 
anything 




Now some more general statements about how PBC may be affecting you as a person. 
How much do the following statements apply to you? 
 
8. I feel guilty that I can’t do 
what I used to do because of 
having PBC 








These statements relate to the possible effects of PBC on your social life and your life 
overall. Thinking of your own situation, how much do you agree or disagree with 
them? 










10. PBC has reduced the quality 














Table 3 Flooring and ceiling effect of PBC-10 












1. I have felt embarrassed because of the 
itching 
5.1  28.7 
2. I ate or drank only a small amount and 
still felt bloated 
4.5 34.5 
3. My mouth was very dry 13.8 23.6 
4. Fatigue interfered with my daily routine 8.4 24.2 
5. I had to force myself to do the things I 
needed to do 
7.4 19.2 
6. If I was busy one day I needed at least 
another day to recover 
13.4 24.3 
7. Because of PBC, I found it difficult to 
concentrate on anything 
4.6 36.1 
8. I feel guilty that I can’t do what I used to 
do because of having PBC 
16.6 41.4 
9. My social life has almost stopped 6.9 32.7 














Table 4: Correlation of the PBC-10 items with the 6 subdomains of the PBC QoL .  
 
Sub-domains 
Symptoms Itch Fatigue Cognition  Social Emotional  
1. I have felt embarrassed 
because of the itching 
 0.921     
2. I ate or drank only a small 
amount and still felt 
bloated 
0.602      
3. My mouth was very dry 0.745      
4. Fatigue interfered with my 
daily routine 
0.898     0.601 
5. I had to force myself to do 
the things I needed to do 
0.905     0.613 
6. If I was busy one day I 
needed at least another 
day to recover 
  0.875   0.566 
7. Because of PBC, I found it 
difficult to concentrate on 
anything 
   0.930  0.567 
8. I feel guilty that I can’t do 
what I used to do because 
of having PBC 
    0.830 0.738 
9. My social life has almost 
stopped 
    0.834 0.596 
10. PBC has reduced the 
quality of my life 












Table 5: Further validation and psychometric properties of PBC-10 





1 Fatigue interfered with my daily routine .857 35% 
2 Because of PBC, I found it difficult to concentrate on 
anything 
.779 41% 
3 PBC has reduced the quality of my life .824 25% 
4 I have felt embarrassed because of the itching .565 41% 
5 I feel guilty that I can’t do what I used to do because of 
having PBC 
.818 44% 
6 I had to force myself to do the things I needed to do .857 37% 
7 My mouth was very dry .617 32% 
8 My social life has almost stopped 
 
.789 35% 
9 I ate or drank only a small amount and still felt bloated .630 33% 
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